ARTICLE

Functional analysis of 11 novel *GBA* alleles

Erika Malini¹, Serena Grossi², Marta Deganuto¹, Camillo Rosano³, Rossella Parini⁴, Silvia Dominisini¹, Roberta Cariati¹, Stefania Zampieri¹, Bruno Bembi¹, Mirella Filocamo² and Andrea Dardis^{*,1}

Gaucher disease is the most frequent lysosomal storage disorder due to the deficiency of the acid β -glucosidase, encoded by the *GBA* gene. In this study, we report the structural and functional characterization of 11 novel *GBA* alleles. Seven single missense alleles, P159S, N188I, E235K, P245T, W312S, S366R and W381C, and two alleles carrying *in cis* mutations, (N188S; G265R) and (E326K; D380N), were studied for enzyme activity in transiently transfected cells. All mutants were inactive except the P159S, which retained 15% of wild-type activity. To further characterize the alleles carrying two *in cis* mutations, we expressed constructs bearing singly each mutation. The presence of G265R or D380N mutations completely abolished enzyme activity, while N188S and E326K mutants retained 25 and 54% of wild-type activity, respectively. Two mutations, affecting the acceptor splice site of introns 5 (c.589-1G>A) and 9 (c.1389-1G>A), led to the synthesis of aberrant mRNA. Unpredictably, family studies showed that two alleles resulted from germline or 'de novo' mutations. These results strengthen the importance of performing a complete and accurate molecular analysis of the *GBA* gene in order to avoid misleading conclusions and provide a comprehensive functional analysis of new *GBA* mutations.

European Journal of Human Genetics (2014) 22, 511–516; doi:10.1038/ejhg.2013.182; published online 11 September 2013

Keywords: Gaucher disease; *GBA* mutations and variants; structural/functional analysis

INTRODUCTION

Gaucher disease (GD) is the most frequent lysosomal storage disorder due to the deficiency of the lysosomal hydrolase, acid β -glucosidase (*GBA*; EC 3.2.1.45). The enzyme is present in the lysosomes of all nucleated cells and cleaves the β -glucosidic linkage of glucosylceramide (GlcCer) yielding glucose and ceramide. The deficiency of *GBA* leads to the progressive lysosomal accumulation of GlcCer and other glycosphingolipids resulting in multiorgan dysfunction.¹

The disease has been classically classified into three major clinical variants based on the presence and progression of central nervous system involvement. Type 1 GD (MIM No. 230800), the most common phenotype, is characterized by enlargement and dysfunction of the liver and spleen, displacement of normal bone marrow by storage cells and bone damage leading to infarctions and fractures. Although type 1 GD is considered a non-neuronopathic form, there is increasing evidence of neurological involvement (ie Parkinson syndrome, seizures, oligophrenia, perceptive deafness). Type 2 GD (MIM No. 230900) is a rare phenotype associated with an acute neurodegenerative course and death at a very early age. These patients commonly present with evidence of brainstem dysfunction followed by progressive deterioration, dysphagia, pyramidal signs, failure to thrive and cachexia during the first month of life. Type 3, the chronic neuronopathic GD (MIM No. 231000), comprises an extremely heterogeneous group of patients who present with either mild or severe systemic disease associated with some form of neurological involvement and with an onset of symptoms that might range from childhood to early adulthood.¹

The human *GBA* is encoded by the *GBA* gene (*GBA*; MIM No. 606463; GenBank accession no. J03059.1), located on chromosome 1q21.

GBA gene is approximately 7.5-kb long and contains 11 exons. A highly homologous 5.5-kb-pseudogene (*GBAP*; MIM No. 606463; GenBank accession no. J03060.1) has been located 16 kb downstream from the active gene.² More than 300 mutations in the *GBA* gene have been reported to date, including all kind of defects such as single base changes, splicing alterations, insertions, partial and total deletions and gene-pseudogene rearrangements (www.hgmd.org).³

GBA protein is synthesized on polyribosomes as a 55-kDa peptide, which is then translocated into the endoplasmic reticulum (ER), where it is modified by the addition of high mannose oligosaccharides, and transported to the trans-Golgi network, from where it is trafficked to the lysosomes.⁴ *GBA* protein is targeted to the lysosomal compartment through a mannose 6-phosphate-independent receptor, the lysosomal integral membrane protein type 2,⁵ a trans-membrane protein mainly found in the lysosomes and late endosomes.^{6,7}

In this study, we report the identification and functional characterization of 11 novel *GBA* mutations.

MATERIALS AND METHODS

Patients

Novel *GBA* mutations were found in 10 patients (pts) diagnosed with GD disease based on the demonstration of reduced *GBA* activity in white blood cells or cultured cell lines (fibroblasts and/or EBV-lymphoblasts). According to clinical parameters, including onset, visceromegaly, bone disease and neurological signs, 7 pts were classified as GD1, 1 pt as GD2 and 2 pts as GD3.¹

Patients' cell lines

Fibroblast and lymphoblast cells from the two patients carrying splicing mutations were cultured and maintained in RPMI medium (EuroClone,

¹Regional Coordinator Centre for Rare Diseases, University Hospital Santa Maria della Misericordia, Udine, Italy; ²U.O.S.D. Centro di Diagnostica Genetica e Biochimica delle Malattie Metaboliche, Istituto G. Gaslini, Genova, Italy; ³Patologia Molecolare Integrata – A.O.U. IRCCS San Martino – IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy and ⁴Rare Metabolic Diseases Unit, Pediatric Clinic, San Gerardo Hospital, Monza, Italy

*Correspondence: Dr A Dardis, Regional Coordinator Center for Rare Diseases, University Hospital Santa Maria della Misericordia, Udine Piazzale Santa Maria della Misericordia 15, Udine 33100, Italy. Tel: +39 0432 554472; Fax: +39 0432 554472; E-mail: dardis.andrea@aoud.sanita.fvg.it

Received 25 February 2013; revised 1 July 2013; accepted 11 July 2013; published online 11 September 2013

Gibco, Paisley, UK) containing 15% of fetal calf serum (FCS) and penicillin/streptomycin in a humidified atmosphere containing 5% CO₂ at 37 °C.

Ethical aspects

Following ethical guidelines, all cell and nucleic acid samples were obtained for analysis and storage with the patients' (and/or a family member's) written informed consent. The consent was sought using a form approved by the local Ethics Committee.

Molecular analysis

Genomic DNA was extracted from peripheral blood leukocytes, cultured fibroblasts and lymphoblasts using QIAamp DNA blood Mini Kit (Qiagen GmbH, Hilden, Germany) or Nucleon BACC3 kit (Amersham Biosciences, Buckinghamshire, UK).

Total RNA was extracted from cell lines using Rneasy mini Kit (Qiagen). First-strand cDNAs were synthesized by Advantage RT-for-PCR Kit (Clontech, Mountain View, CA, USA) and random hexamer primers.

GBA gene exons and most intronic regions were PCR amplified using primers designed by reference to the genomic sequence (GenBank J03059.1) to selectively amplify the gene and not the homologous pseudogene (GenBank J03060.1) as previously described by Koprivica *et al.*⁸

Reverse transcriptase-PCR (RT-PCR) was performed using sets of primers designed by reference to the *GBA* mRNA sequence (GenBank accession No. NM_000157.3), as previously reported.⁹ PCR products were cloned into the TOPO TA Cloning KIT (with pCR2.1-TOPO vector) (Invitrogen, San Diego, CA, USA), according to the manufacturer's instructions. PCR and RT-PCR products were analyzed by automated sequencing (ABI Prism 3500xl genetic analyzer, Applied Biosystems, Foster City, CA, USA). Putative mutations were confirmed by sequencing duplicate PCR products and by the DNA analysis from parents and relatives whenever possible. The issue of whether novel *GBA* sequence alterations detected were causative mutations or neutral polymorphisms was addressed by (i) searching dbSNP <http://www.ncbi.nlm.nih.gov/SNP> for their presence, (ii) screening 100 alleles from healthy control subjects for each alteration, and (iii) '*in vitro*' expression studies and structural 3D analysis.

Novel *GBA* alleles have been submitted to the locus-specific mutation database: <http://www.hgvs.org/dblist/glsdb.htm>.

Variable number tandem repeat (VNTR) profiles were analyzed by Cell ID System Kit (Promega, Madison, WI, USA) according to the manufacturer's instructions.

Site-directed mutagenesis

The novel point mutations of *GBA* gene were introduced in the wild-type full-length cDNA cloned in pcDNA3 already described¹⁰ by site-directed mutagenesis using the Quikchange Site-directed Mutagenesis Kit (Stratagene, Cedar Creek, TX, USA) according to manufacturer's instructions. The sequence of primers used for mutagenesis are listed in Supplementary Table S1.

Mutation nomenclature

All mutations are described according to the current mutation nomenclature guidelines (<http://www.hgvs.org/mutnomen>), ascribing the A of the first ATG translation initiation codon as nucleotide +1 (GenBank NM_000157.3).^{11,12} Traditional amino-acid residue numbering, which excludes the first 39 amino acids of the leader sequence, has nevertheless also been provided in parentheses and designed without the prefix 'p'.

Transient transfection

Human HEK293 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% FCS, 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco, Paisley, UK) at 37 °C in a humidified atmosphere enriched with 5% (v/v) CO₂. Cells were transfected with the 4 µg of wild-type and mutant constructs using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.

After 72 h, cells were harvested and the cellular extracts were analyzed for *GBA* activity.

GBA activity

Total amount of protein in cell lysates was determined by Lowry's method. Ten micrograms of the protein were assayed for *GBA* activity in 150 µl of buffer citrato 0.1 M –phosphate 0.2 M pH 5.2 containing 0.15% taurocholate (w/v, Calbiochem, La Jolla, CA, USA) in the presence of 7.5 mM 4-MUG for 2 h at 37 °C. The reaction was stopped by the addition of 2 ml of stop solution (buffer carbonato 0.5 M, pH 10.7). The amount of 4-methyl-umbeliferone (4-MU) was quantified using a Gemini XPS Spectrometer (Molecular Devices, Sunnyvale, CA, USA) (excitation length: 340 nm; emission: 495 nm).¹³ The Hek293 endogenous *GBA* activity was measured in cells transfected with empty pcDNA3 vector and subtracted from activity obtained in cells transfected with the WT and mutant constructs. Results were expressed as the percentages of wild-type enzyme activity.

Structural 3D analysis

Visual inspection of *GBA* three-dimensional structure¹⁴ (PDB code 1OGS) and amino-acid substitutions were carried over using the program Coot;¹⁵ energy minimization using the program DISCOVER3 from the InsightII program suite (Accelrys, Inc., San Diego, CA, USA). Figures were drawn using the program Chimera.¹⁶

The non-canonical disulfide bridges were predicted using the program <http://clavius.bc.edu/~clotelab/DiANNA/>.

RESULTS AND DISCUSSION

The 11 novel *GBA* alleles of the present study have been identified during the routine molecular testing of GD patients performed at two Italian laboratory reference centers (Udine and Genoa). Among them, 9 alleles carried 11 missense mutations that occurred as (i) single point mutations c.592C>T [p.P198S (P159S)], c.680A>T [p.N227I (N188I)], c.820G>A [p.E274K (E235K)], c.850C>A [p.P284T (P245T)], c.1052G>C [p.W351S (W312S)], c.1215C>A [p.S405R (S366R)], c.1260G>C [p.W420C (W381C)] or (ii) *in cis* on the same allele: c.680A>G;c.910G>C [p.N227S;p.G304R (N188S;G265R)], c.1093G>A;c.1255G>A [p.E365K;p.D419N (E326K;D380N)]. Finally, two were splice site alterations c.589-1G>A, [p.I197Vfs*7 (I158Vfs*7)] and c.1389-1G>A [p.L464Sfs*24 (L425Sfs*24)] (Table 1).

Table 1 Characteristics of the *GBA* gene mutations identified in Gaucher disease patients

Genomic location	Site of nucleotide substitution ^a	Predicted effect on protein	
		Amino-acid change ^b	Traditional numbering
Ex 6	c.592C>T	p.P198S	P159S
Ex 6	c.680A>T	p.N227I	N188I
Ex 7	c.820G>A	p.E274K	E235K
Ex 7	c.850C>A	p.P284T	P245T
Ex 8	c.1052G>C	p.W351S	W312S
Ex 8	c.1215C>A	p.S405R	S366R
Ex 9	c.1260G>C	p.W420C	W381C
Ex 6 and Ex 7	c.680A>G;c.910G>C	p.N227S;p.G304R	N188S;G265R
Ex 8 and Ex 9	c.1093G>A;c.1255G>A	p.E365K;p.D419N	E326K;D380N
Intr 5	c.589-1G>A	p.I197Vfs*7	I158Vfs*7
Intr 9	c.1389-1G>A	p.L464Sfs*24	L425Sfs*24

Abbreviations: Ex, exon; Intr, intron; *GBA* gene, GenBank accession no. J03059.1.

^a*GBA* cDNA accession number NM_000157.3.

^b*GBA* cDNA accession number NP_000148.2.

Functional analysis of novel missense GBA alleles

The impact of missense mutations on GBA activity was evaluated by *in vitro* expression of mutant constructs in Hek293 cells and the analysis of the expressed GBA activity. As a negative control, Hek293 cells were transfected with empty pcDNA3 vector. The activity of proteins bearing the common p.N409S (N370S) and p.L483P (L444P) mutations were also analyzed. No changes in the viability of transfected cells were observed.

As shown in Figure 1, GBA proteins carrying the changes p.N227I (N188I), p.E274K (E235K), p.P284T (P245T), p.W351S (W312S), p.S405R (S366R) and p.W420C (W381C) presented a very low or absent GBA activity as compared with the wild-type protein, while the p.P198S (P159S) retained a residual activity of 15% of wild type.

Figure 1 Functional analysis of novel missense GBA alleles. Acid β -glucosidase activity in Hek293 cells transiently transfected with the wild-type and mutant constructs was measured using the fluorogenic substrate 4-MU-D-glucopyranoside. Values are expressed as the percentages of wild-type enzyme activity. The data are shown as mean $\pm$ SD of three different experiments, each performed in triplicate.

Both alleles carrying two *in cis* mutations [p.N227S;p.G304R (N188S;G265R)] and [p.E365K;p.D419N (E326K;D380N)] led to the expression of completely inactive proteins. To further characterize these alleles, we expressed *in vitro* constructs bearing singly each mutation. Although the G265R and D380N mutants expressed no activity, both N188S and E326K mutants retained a residual activity of 25 and 54%, respectively. Our data are in line with previous *in vitro* studies, which described the N188S as a modifier variant¹⁷ and the E326K as a very mild mutation.¹⁸ However, while the N188S has been found as a single mutation in GD patients, the E326K has always appeared in association with another mutation on the same allele. As previously reported, mutants N370S and L444P retained a residual activity of 38 and 13% of WT, respectively.¹⁹

Structural analysis

To shed further light on the possible consequences of these amino-acid changes at protein level, we performed a structural protein analysis based on the 3D model of the GBA. All mutated residues belong to domain III, which contains the catalytic site¹⁴ (Figure 2). Significantly, the computational analysis revealed that, apart from p.P198S (P159S), p.G304R (G265R) and p.E365K (E326K), all mutations are directly or indirectly involved in substrate recognition (Supplementary Table S2).

Mutations affecting residues located on the protein surface may interfere with the correct coupling of GBA with protein partners [p.P198S (P159S), p.G304R (G265R), p.E365K (E326K)] or indirectly interfere with the catalytic activity of p.N227 (N188): in particular, the '*in vitro*' expression of this latter residue replaced with isoleucine or serine showed that the p.N227I (N188I) mutant was completely inactive, whereas the p.N227S (N188S) mutant retained a quite high residual activity. Indeed, the replacement of a small asparagine with a big and hydrophobic isoleucine (N188I) *versus* a small and polar serine (N188S) is likely to impact upon the correct substrate positioning.

Figure 2 Location of GBA mutations on the X-ray structural model. Catalytic domain is represented in green while the N terminal and C terminal domains are drawn in orange and red, respectively. Positions of the mutations are indicated in yellow.

Functional analysis of splicing mutations

Two intronic mutations affected the invariant acceptor 'G' nucleotide splice site of intron 5 (c.589-1G>A) and intron 9 (c.1389-1G>A). To analyze the possible effect on the mRNA splicing process, we first evaluated the splice site signal strengths using two splicing prediction programs (ME=Maximum Entropy available at: http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq_acc.html²⁰ and NN=Neural Network available at http://www.fruitfly.org/seq_tools/splice.html²¹). Both programs predicted that the mutated sequence would no longer be recognized as a 3' splice site or would be recognized with a much lower score than the wild-type sequence (Table 2).

To confirm the impact of these two mutations upon the *GBA* mRNA splicing process *in vivo*, a RT-PCR analysis on mRNAs from the cultured fibroblasts of the respective patients was carried out. Sequence analysis of the RT-PCR products confirmed the exon-6 skipping resulting from c.589-1G>A and showed instead that the intronic c.1389-1G>A led to a slippage of the splice site of four nucleotides in an attempt to restore the invariant acceptor 'AG' nucleotide splice site of intron 9 with the close c.1392G nucleotide of exon 10 (Figure 3). However, this cryptic acceptor splice site was not predicted by either of the *in silico* analysis tools used in this study.

Both intronic mutations, c.589-1G>A and c.1389-1G>A, predicting to introduce premature stop codons resulted in the frameshifts p.I197Vfs*7 and p.L464Sfs*24, respectively.

Phenotype-genotype considerations

As mentioned above, almost all new mutant alleles were predicted to abrogate the *GBA* activity or cause severe splicing defects (Figure 1 and 3). However, as shown in Table 3, whenever these deleterious alleles were in compound heterozygous patients in association with the common p.N409S (N370S) mutation caused GD type 1; likewise, alleles p.N227I (N188I) and p.E274K (E235K) in association with already known deleterious lesions, p.R170C (R131C) and p.L483P (L444P), respectively, underlay the severe neuronopathic GD type 2.

Much less expected was the GD type 1 phenotype in the patient compound heterozygous for the new [p.W351S (W312S)] mutation, which completely abrogates the *GBA* activity (Figure 1) in association

Table 2 Predicted effect of *GBA* splicing mutations using bioinformatics tool

Mutation	Splicing program	
	ME	NN
c.589-1G>A	WT 3' ss 9.04	WT 3' ss 0.98
	Mutant 3' ss 0.29	Mutant 3' ss NR
c.1389-1G>A	WT 3' ss 7.66	WT 3' ss 0.38
	Mutant 3' ss 1.09	Mutant 3' ss NR

Abbreviations: ME, Maximum entropy, NN, neural network, NR, not recognized because below detection threshold; WT, wild type.

Table 3 Phenotype-genotype correlation analysis

Genotype ^a		
Allele 1	Allele 2	Phenotype
[p.P284T (P245T)] [p.S405R (S366R)] [p.W420C (W381C)] [p.I197Vfs*7 (I158Vfs*7)] [p.L464Sfs*24 (L425Sfs*24)]	[p.N409S (N370S)]	1
[p.W351S (W312S)] [p.N227I (N188I)] [p.E274K (E235K)]	[p.L483P (L444P)] [p.R170C (R131C)] [p.G241R (G202R)]	1 2 2
[p.E365K;p.D419N (E326K;D380N)] [p.N227S;p.G304R (N188S;G265R)]	[p.P198S (P159S)] Unknown	1 3

^aTraditional amino-acid residue numbering, which excludes the first 39 amino acids of the leader sequence, has been provided in parentheses and designed without the prefix 'p.'

Figure 3 Functional analysis of the two splicing mutations. Results of the reverse transcriptase-PCR analysis on mRNA samples showed that the c.589-1G>A mutation caused the abrogation of intron 5 acceptor 3' splice site (ss) and the skipping of exon 6 (a), whereas the c.1389-1G>A mutation led to the abrogation of intron 9 acceptor 3' ss and activation of alternative 3' ss in exon 10 (4 nucleotides downstream of the canonical 3' ss using the c.1392G nucleotide) (b). Normal splicing is depicted as unbroken green lines and abnormal splicing as dotted fuchsia lines; blue boxes indicate normally spliced exons and fuchsia boxes genomic regions involved in the altered splicing process.

with the [p.L483P (L444P)]. This patient, who was diagnosed as having GD and treated with ERT at the age of 9 years, is indeed a 22-year-old woman with no evidence of clinical or subclinical neurological involvement. In an attempt to exclude the theoretical possibility of additional *in cis* mutations, both the alleles of this patient have been entirely sequenced. In circumstances like these, it is particularly difficult to evaluate how the therapy, on one hand, and other modifying genetic or nongenetic factors, on the other hand, might have contributed to such an unexpected clinical course of the disease.

Splenomegaly, anemia and growth retardation were the presenting symptoms of a 5-year-old GD1 patient compound heterozygous for two new alleles: one carrying two *in cis* mutations [p.E365K;p.D419N (E326K;D380N)] in association with the p.P198S (P159S) allele. The patient, who has been treated with ERT since the age of 6 years, is currently an 11-year-old girl with no evidence of neurological involvement. It is therefore likely that 15% of residual activity retained by the protein bearing the p.P198S (P159S) mutation (Figure 1) might account for the mild phenotype of the patient. The '*in vitro*' expression findings appear also to be in line with the structural protein analysis (Figure 3).

Finally, the other allele carrying two *in cis* mutations [p.N227S;p.G304R (N188S;G265R)] was found in a GD type III patient, of whom the second allele remained undetermined likely owing to some molecular lesions escaping conventional sequencing analysis.²² However, the limited samples from the patient did not allow us to extend the analysis for revealing lesions such as recombinations, large deletions or deep intronic mutations potentially altering the mRNA processing. Even in the absence of a complete genotype, some important considerations can be made in this patient based on the presented results. Results of the '*in vitro*' expression of each single mutation showed that while the enzymatic activity of p.G304R (G265R) mutant was nearly absent, the p.N227S (N188S) mutant retained a quite high residual activity, as also reported in previous studies.¹⁷ Conversely, the cumulative effect of the double mutant seemed to be highly deleterious as the *in vitro* expressed activity was almost undetectable. Interestingly, this patient developed myoclonic epilepsy, previously reported as associated with the p.N227S (N188S) mutation.^{23,24} It is therefore likely that myoclonic epilepsy is always determined by the p.N227S (N188S) both as single mutation and as part of a double-mutant allele.

Even though some phenotype-genotype considerations can be supported by the presented results, it must be acknowledged that the *in vitro* expression model is not entirely suitable to study the effect of *GBA* mutations on protein processing, one of the main factors that determine GD severity.²⁵ In fact, even if some *GBA* mutations lead to the synthesis of partially active proteins, they are retained in the ER, due to their inability to fold correctly, undergo ER-associated proteasomal degradation and never reach the lysosomes.²⁶ In our experimental set, the overexpression of *GBA* proteins results in a saturation of the systems involved in their trafficking and degradation, rendering the model not suitable to evaluate protein fate.

Finally, it is important to keep in mind that besides *GBA* mutations, genetic variations in proteins involved in *GBA* processing may also have a role in the phenotypic expression of GD.

Family studies

The mutation analysis was extended wherever possible to all the family members. Quite unpredictably, we came across two germline or '*de novo*' mutations, the p.D419N (D380N), found in association with another point mutation in the same allele [p.E365K;p.D419N

(E326K;D380N)] and the [p.G241R (G202R)]. As both mutations occurred on the paternally derived allele, various samples were used to exclude the theoretical possibility of a sample exchange as well as VNTR profiles were compared in the two families to exclude mispaternity. So far, '*de novo*' or germline mutations appears to be extremely rare in Gaucher disease.^{27,28} However, since such events have significant implications for genetic counselling, we emphasize the importance of the families' studies. Gonadal mosaicism could not be formally excluded in the respective patient's fathers who were found to be negative with respect to a specific mutation. Therefore, in clinical practice, prenatal testing is recommended for those couples still potentially at risk.

These results strengthen the importance of performing a complete and accurate molecular analysis of the *GBA* gene in order to avoid misleading conclusions and to provide an appropriate genetic counselling. In addition, they provide a comprehensive functional analysis of new *GBA* mutations.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by a grant of the Italian Ministry of Health PRF 37/08 '*Clinical History and long-term cost-effectiveness of Enzyme Replacement Therapy (ERT) for Gaucher Disease in Italy*'. Some samples were obtained from the 'Cell Line and DNA Biobank from Patients Affected by Genetic Diseases' (G. Gaslini Institute) – Telethon Network of Genetic Biobanks (Project No. GTB12001A). We thank the Fondazione Pierfranco and Luisa Mariani of Milano for providing financial support for clinical assistance to the metabolic patients.

- Beutler E, Grabowski GA: Gaucher disease; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds). *The Metabolic and Molecular Basis of Inherited Disease*. New York, NY, USA: McGraw-Hill, 2001; Vol 3, pp 3635–3668.
- Horowitz M, Wilder S, Horowitz Z: The human glucocerebrosidase gene and pseudogene: structure and evolution. *Genomics* 1989; **4**: 87–96.
- Stenson PD, Ball EV, Mort M *et al*: Human Gene Mutation Database (HGMD): 2003 update. *Hum Mutat* 2003; **21**: 577–581.
- Erickson AH, Ginns EI, Barranger JA: Biosynthesis of the lysosomal enzyme glucocerebrosidase. *J Biol Chem* 1985; **260**: 14319–14324.
- Reczek D, Schwake M, Schröder J *et al*: LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. *Cell* 2007; **131**: 770–783.
- Fukuda M: Lysosomal membrane glycoproteins. Structure, biosynthesis, and intracellular trafficking. *J Biol Chem* 1991; **266**: 21327–21330.
- Fujita H, Takata Y, Kono A *et al*: Isolation and sequencing of a cDNA clone encoding the 85 kDa human lysosomal sialoglycoprotein (hLGP85) in human metastatic pancreas islet tumor cells. *Biochem Biophys Res Commun* 1992; **184**: 604–611.
- Koprivica V, Stone DL, Park JK *et al*: Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. *Am J Hum Genet* 2000; **66**: 1777–1786.
- Filocamo M, Mazzotti R, Stroppiano M *et al*: Analysis of the glucocerebrosidase gene and mutation profile in 144 Italian gaucher patients. *Hum Mutat* 2002; **20**: 234–235.
- Miocic S, Filocamo M, Dominissini S *et al*: Identification and functional characterization of five novel mutant alleles in 58 Italian patients with Gaucher disease type 1. *Hum Mutat* 2005; **25**: 100.
- den Dunnen JT, Antonarakis SE: Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. *Hum Mutat* 2000; **15**: 7–12.
- den Dunnen JT, Paalman MH: Standardizing mutation nomenclature: why bother? *Hum Mutat* 2003; **22**: 181–182.
- Raghavan SS, Topol J, Kolodny EH: Leukocyte beta-glucosidase in homozygotes and heterozygotes for Gaucher disease. *Am J Hum Genet* 1980; **32**: 158–173.
- Dvir H, Harel M, McCarthy AA *et al*: X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. *EMBO Rep* 2003; **4**: 704–709.
- Emsley P, Cowtan K: Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* 2004; **60**: 2126–2132.
- Petersen EF, Goddard TD, Huang CC *et al*: UCSF Chimera—a visualization system for exploratory research and analysis. *J Comput Chem* 2004; **25**: 1605–1612.

- 17 Montfort M, Chabás A, Vilageliu L, Grinberg D: Functional analysis of 13 *GBA* mutant alleles identified in Gaucher disease patients: pathogenic changes and "modifier" polymorphisms. *Hum Mutat* 2004; **23**: 567–575.
- 18 Horowitz M, Pasmanik-Chor M, Ron I, Kolodny EH: The enigma of the E326K mutation in acid β -glucocerebrosidase. *Mol Genet Metab* 2011; **104**: 35–38.
- 19 Alfonso P, Rodríguez-Rey JC, Gañán A *et al*: Expression and functional characterization of mutated glucocerebrosidase alleles causing Gaucher disease in Spanish patients. *Blood Cells Mol Dis* 2004; **32**: 218–225.
- 20 Yeo G, Burge CB: Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. *J Comput Biol* 2004; **11**: 377–394.
- 21 Reese MG, Eeckman FH, Kulp D, Haussler D: Improved splice site detection in Genie. *J Comput Biol* 1997; **4**: 311–323.
- 22 Beutler E, Gelbart T: Erroneous assignment of Gaucher disease genotype as a consequence of a complete gene deletion. *Hum Mutat* 1994; **4**: 212–216.
- 23 Filocamo M, Mazzotti R, Stroppiano M *et al*: Early visual seizures and progressive myoclonus epilepsy in neuronopathic Gaucher disease due to a rare compound heterozygosity (N188S/S107L). *Epilepsia* 2004; **45**: 1154–1157.
- 24 Kowarz L, Goker-Alpan O, Banerjee-Basu S *et al*: Gaucher mutation N188S is associated with myoclonic epilepsy. *Hum Mutat* 2005; **26**: 271–273.
- 25 Bendikov-Bar I, Horowitz M: Gaucher disease paradigm: from ERAD to comorbidity. *Hum Mutat* 2012; **33**: 1398–1407.
- 26 Ron I, Horowitz M: ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. *Hum Mol Genet* 2005; **14**: 2387–2398.
- 27 Filocamo M, Bonuccelli G, Mazzotti R *et al*: Somatic mosaicism in a patient with Gaucher disease type 2: implication for genetic counseling and therapeutic decision-making. *Blood Cells Mol Dis* 2000; **26**: 611–612.
- 28 Saranjam H, Chopra SS, Levy H: A germline or de novo mutation in two families with Gaucher disease: implications for recessive disorders. *Eur J Hum Genet* 2013; **21**: 115–117.

Supplementary Information accompanies this paper on European Journal of Human Genetics website (<http://www.nature.com/ejhg>)